Analysts Adjust Biohaven Price Targets Following FDA News

Following the FDA's acceptance of Biohaven's resubmitted NDA for Vyglxia, Deutsche Bank raised its price target for the company to $26 from $20, maintaining a Buy rating. RBC also increased its price target to $22 from $19, keeping a Sector Perform rating with a speculative risk designation. These changes indicate positive analyst sentiment regarding the drug's regulatory progress and its potential impact on Biohaven's valuation.